Paper Details

  1. Home
  2. Paper Details

Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in non-intervention Safety Study in mCRPC popUlation for long-teRm Evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practice.

Author: BayhInga, BourreJean-Cyril, DizdarevicSabina, DuYong, EsslerMarkus, EzziddinSamer, KalinovskýJán, PaganelliGiovanni, PetersenPeter Meidahl, ValdagniRiccardo, VersariAnnibale, la FougèreChristian

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.

Overview

This interim analysis of 583 patients with bone metastatic castration-resistant prostate cancer receiving radium-223 in routine clinical practice assessed the safety of the drug, considering prior chemotherapy use. The safety profile was comparable to previous studies, with a higher proportion of patients who had received prior chemotherapy experiencing hematological adverse events. This suggests that prior chemotherapy may affect bone marrow function and increase hematological toxicity.
Paper Details　
Original Abstract of the Article :
PURPOSE: REASSURE is a global, prospective, non-interventional study to assess long-term safety of radium-223 in patients with bone metastatic castration-resistant prostate cancer. Here we report an interim analysis of patients according to previous use of chemotherapy. METHODS: Radium-223 was admi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6451709/

データ提供：米国国立医学図書館（NLM）

Long-Term Safety of Radium-223 in Prostate Cancer

Navigating the complex world of cancer treatment is like exploring a vast, unknown desert. This research delves into the safety of radium-223, a treatment for bone metastatic castration-resistant prostate cancer. The researchers conducted a long-term safety study, examining patients who had previously received chemotherapy. Their meticulous analysis, like mapping a desert, revealed key insights into the effects of radium-223 on these patients. The researchers found that radium-223 appears to have a similar safety profile to other treatments, regardless of prior chemotherapy use. However, they observed a higher incidence of hematological adverse events in patients who had previously received chemotherapy. These findings are vital for informing treatment decisions and optimizing patient care.

Prior Chemotherapy Impacts Safety

This research suggests that prior chemotherapy exposure can influence the safety profile of radium-223. This is an important consideration for doctors who treat patients with bone metastatic castration-resistant prostate cancer. It's like navigating a desert - previous journeys may have left an impact on the landscape, shaping the path ahead.

Understanding the Implications

Understanding these findings is crucial for both doctors and patients, allowing them to make informed decisions about treatment strategies. Navigating the complex terrain of cancer treatment is a collaborative journey. Like a group of travelers in a desert, the patient and doctor must work together to choose the best path forward.

Dr. Camel's Conclusion

This research provides valuable insights into the long-term safety of radium-223 in prostate cancer patients, especially those with prior chemotherapy exposure. It highlights the importance of careful monitoring and understanding the potential risks and benefits of this treatment. Like navigating a desert, careful planning and awareness of the landscape are crucial for successful outcomes.

Date :
  1. Date Completed 2020-05-25
  2. Date Revised 2020-05-25
Further Info :

Pubmed ID

30637501

DOI: Digital Object Identifier

PMC6451709

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.